Development and clinical utility of blood-based ddPCR assays for rare variant testing

Dr. Gary Pastano, Chief Development Officer at Biodesix, discusses the development and clinical utility of blood-based droplet digital PCR (ddPCR) assays for rare variant detection in lung cancer. He highlights Biodesix’s GeneStrat^® test, their focus on early and personalized diagnostics for lung diseases, and their strategic partnerships supporting innovation in oncology diagnostics. The talk also covers assay development, clinical validation, and real-world applications in monitoring disease progression